Kamada (KMDA) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Q1 2026 results: Kamada is expected to report before the open on May 13 (call 8:30 AM ET), with analysts forecasting $0.12 EPS and roughly $46.72M in revenue.
• Recent miss and analyst outlook: In the prior quarter Kamada reported $0.06 EPS versus $0.09 expected and $44.68M in revenue, while analysts now model about $1.00 EPS for the current and next fiscal years and assign a consensus price target of $13 ("Moderate Buy").
• Stock & dividend snapshot: Shares opened at $8.21 (12‑month range $6.50–$9.35) with a market cap of ~$472M and P/E of 23.46; the company paid a $0.25 annual dividend on April 7 (ex‑dividend March 23) with a reported payout ratio of 54.29%.

Kamada (NASDAQ:KMDA - Get Free Report) will likely be issuing its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of $0.12 per share and revenue of $46.7220 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 8:30 AM ET.

Kamada (NASDAQ:KMDA - Get Free Report) last issued its quarterly earnings data on Wednesday, March 11th. The biotechnology company reported $0.06 earnings per share for the quarter, missing analysts' consensus estimates of $0.09 by ($0.03). Kamada had a net margin of 11.19% and a return on equity of 7.72%. The firm had revenue of $44.68 million during the quarter, compared to analysts' expectations of $145.07 million. On average, analysts expect Kamada to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Kamada Trading Down 1.0%

Shares of NASDAQ KMDA opened at $8.21 on Wednesday. Kamada has a twelve month low of $6.50 and a twelve month high of $9.35. The stock has a 50 day moving average of $8.53 and a two-hundred day moving average of $7.82. The stock has a market cap of $472.16 million, a P/E ratio of 23.46, a P/E/G ratio of 0.63 and a beta of 0.86.

Kamada Announces Dividend

The company also recently disclosed an annual dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd were paid a $0.25 dividend. The ex-dividend date was Monday, March 23rd. This represents a yield of 305.0%. Kamada's payout ratio is currently 54.29%.

Institutional Investors Weigh In On Kamada

Several large investors have recently modified their holdings of the stock. Aristides Capital LLC raised its stake in shares of Kamada by 4.5% during the fourth quarter. Aristides Capital LLC now owns 33,015 shares of the biotechnology company's stock worth $233,000 after purchasing an additional 1,430 shares during the last quarter. NewEdge Advisors LLC raised its stake in shares of Kamada by 4.2% during the third quarter. NewEdge Advisors LLC now owns 52,668 shares of the biotechnology company's stock worth $366,000 after purchasing an additional 2,125 shares during the last quarter. Barclays PLC raised its stake in shares of Kamada by 417.1% during the fourth quarter. Barclays PLC now owns 4,788 shares of the biotechnology company's stock worth $34,000 after purchasing an additional 3,862 shares during the last quarter. Two Sigma Investments LP raised its stake in shares of Kamada by 4.3% during the third quarter. Two Sigma Investments LP now owns 109,589 shares of the biotechnology company's stock worth $761,000 after purchasing an additional 4,504 shares during the last quarter. Finally, Man Group plc grew its holdings in Kamada by 19.9% during the fourth quarter. Man Group plc now owns 34,294 shares of the biotechnology company's stock worth $242,000 after acquiring an additional 5,684 shares during the period. Hedge funds and other institutional investors own 20.38% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on KMDA. Stifel Nicolaus set a $11.00 price objective on Kamada in a research note on Wednesday, March 11th. Weiss Ratings reiterated a "buy (b-)" rating on shares of Kamada in a research note on Thursday, January 22nd. Wall Street Zen cut Kamada from a "strong-buy" rating to a "buy" rating in a research note on Saturday, March 14th. Finally, Benchmark reiterated a "buy" rating on shares of Kamada in a research note on Thursday, March 12th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $13.00.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.